Latest News

  • 27 Jul 2015

    TapImmune Announces Finalization of License Agreement With M...

    Agreement Will Allow for the Transfer of IND from Mayo to TapImmune and the Initiation of Company-Sponsored Phase 2 Clinical Trials SEATTLE, July 27, 2015 /PRNewswire/ — TapImmune, Inc. (TPIV), a clinical stage cancer immunotherapy company, is pleased to announce that the Company has...

    more >

  • 23 Jun 2015

    TapImmune Reports Robust Immune Responses Generated in 19 of...

    Phase I Trial analyses shows safety and positive immune response data SEATTLE, June 23, 2015 /PRNewswire/ – TapImmune Inc. (TPIV) is pleased to report the completion of data analysis from patients treated in a Phase I clinical trial. In this Phase 1 trial conducted at the Mayo Clinic in...

    more >